advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at stage ii usefulness of prognostic markers e-cadherin and ki67辅助化疗的优势在ii期三阴性乳腺癌患者的预后标记上皮和ki67的实用性.pdfVIP

Kashiwagi et al. Breast Cancer Research 2011, 13:R122 /content/13/6/R122 RESEARCH ARTICLE Open Access Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67 1 1,2* 1 1 3 Shinichiro Kashiwagi , Masakazu Yashiro , Tsutomu Takashima , Naoki Aomatsu , Katsumi Ikeda , Yoshinari Ogawa3, Tetsuro Ishikawa1 and Kosei Hirakawa1 Abstract Introduction: Triple-negative breast cancer (TNBC), which is characterized by negativity for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), is a high risk breast cancer that lacks specific targets for treatment selection. Chemotherapy is, therefore, the primary systemic modality used in the treatment of this disease, but reliable parameters to predict the chemosensitivity of TNBC have not been clinically available. Methods: A total of 190 TNBC patients who had undergone a curative resection of a primary breast cancer were enrolled. The adjuvant chemotherapy was performed for 138 (73%) of 190 TNBC cases; 60 cases had an anthracyclin-based regimen and 78 a 5-fluorouracil-based regimen. The prognostic value of E-cadherin, Ki67 and p53 expression in the outcome of TNBC patients with adjuvant chemotherapy was evaluated by immunohistochemistry. Results: The adjuvant therapy group, especially those with Stage II TNBC, had a more favorable prognosis than the surgery only group (P = 0.0043), while there was no significant difference in prognosis between the anthracyclin- based regimen and 5-fluorouracil-based regimen. Patients with E-cadherin-negative and Ki67-positive expression showed significantly worse overall survival time than those wi